- Home
- HWH vs MRNS Comparison
HWH vs MRNS Comparison
Compare HWH & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HWH
- MRNS
- Stock Information
- Founded
- HWH 2021
- MRNS 2003
- Country
- HWH United States
- MRNS United States
- Employees
- HWH N/A
- MRNS N/A
- Industry
- HWH Other Pharmaceuticals
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- HWH Health Care
- MRNS Health Care
- Exchange
- HWH Nasdaq
- MRNS Nasdaq
- Market Cap
- HWH 18.6M
- MRNS 19.0M
- IPO Year
- HWH N/A
- MRNS 2014
- Fundamental
- Price
- HWH $0.72
- MRNS $0.30
- Analyst Decision
- HWH
- MRNS Buy
- Analyst Count
- HWH 0
- MRNS 12
- Target Price
- HWH N/A
- MRNS $4.28
- AVG Volume (30 Days)
- HWH 9.5K
- MRNS 6.6M
- Earning Date
- HWH 11-23-2024
- MRNS 11-12-2024
- Dividend Yield
- HWH N/A
- MRNS N/A
- EPS Growth
- HWH N/A
- MRNS N/A
- EPS
- HWH N/A
- MRNS N/A
- Revenue
- HWH $1,174,367.00
- MRNS $31,466,000.00
- Revenue This Year
- HWH N/A
- MRNS $20.74
- Revenue Next Year
- HWH N/A
- MRNS $32.38
- P/E Ratio
- HWH N/A
- MRNS N/A
- Revenue Growth
- HWH 44.55
- MRNS 1.63
- 52 Week Low
- HWH $0.41
- MRNS $0.26
- 52 Week High
- HWH $12.70
- MRNS $11.26
- Technical
- Relative Strength Index (RSI)
- HWH 47.44
- MRNS 25.07
- Support Level
- HWH $0.69
- MRNS $0.29
- Resistance Level
- HWH $0.77
- MRNS $0.37
- Average True Range (ATR)
- HWH 0.06
- MRNS 0.04
- MACD
- HWH -0.00
- MRNS 0.02
- Stochastic Oscillator
- HWH 45.63
- MRNS 17.95
About HWH HWH International Inc.
HWH International Inc is a purpose-driven lifestyle company enabling home-based people in the new GIG economy to create lasting wealth. Developing new pathways in the aid of helping people in their pursuit of Health, Wealth and Happiness.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.